SomnoMed (ASX:SOM) Research & Development: A$0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SOM SomnoMed Ltd ASX:SOM
49 GF Score
Price A$0.46
GF Value A$0.45
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Research & Development?

SomnoMed ASX:SOM 49 Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus rates ASX:SOM with a GF Score™ of 49/100 and a GF Value™ of A$0.45 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. SomnoMed's Research & Development for the six months ended in Dec. 2025 was A$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.0 Mil.

SomnoMed  (ASX:SOM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SomnoMed Research & Development Related Terms

SomnoMed Research & Development Historical Data

* Premium members only.

The historical data trend for SomnoMed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed Research & Development Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.76 10.92 12.24 13.48 16.24

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:SOM
49GF Score
SomnoMed Ltd ASX:SOM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.0 Mil mean?
SomnoMed (ASX:SOM) has a Research & Development of A$0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on SomnoMed and its competitors.
Is SomnoMed's Research & Development too high?
SomnoMed's current Research & Development is A$0.0 Mil. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Research & Development compare to ABT and SYK?
SomnoMed's Research & Development of A$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SomnoMed and its competitors. SomnoMed's current Research & Development is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Fairly Valued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.46 — trading 2.2% above its estimated fair value. The current Research & Development is A$0.0 Mil. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (ASX:SOM) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of A$0.46 is trading 2.2% above its estimated GF Value™ of A$0.45. GuruFocus considers SomnoMed to be Fairly Valued.

Key valuation signals for ASX:SOM:

  • Research & Development: A$0.0 Mil
  • GF Value™: A$0.45 vs. price of A$0.46 (2.2% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges SOMNF:USARJV:Germany
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for ASX:SOM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price
A$0.45
GF Value